Key Takeaways Genmab shares jumped 21.9% in a month on plans to acquire Merus for $8 billion in cash.The acquisition adds petosemtamab, a late-stage oncology candidate, to GMAB's proprietary pipeline.GMAB expects petosemtamab to drive growth, with potential billion-dollar sales contributions by 2029.Shares of Genmab A/S (GMAB) have rallied 21.9% in a month. The stock price rally was observed after the company signed a definitive agreement in late September to acquire Merus N.V. (MRUS) for $97 per share in c ...